Incyte to start testing drug in PV patients
Incyte president Paul A. Friedman, MD reported that progress on their COMFORT-1 trial in myelofibrosis patients was strong enough to allow them to test the compound in polycythemia vera patients. They are expected to initiate the Phase III program for PV patients in the fourth quarter of 2010. COMFORT-1 is a JAK2 inhibitor.
The full article is available by clicking here.